Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Rindopepimut vaccine and bevacizumab combination therapy: improving survival rates in relapsed glioblastoma patients?

Rindopepimut vaccine and bevacizumab combination therapy: improving survival rates in relapsed glioblastoma patients? Immunotherapy. 2015; 7(6):603-6.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.